Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin effects on aging markers in type 2 diabetes mellitus
ChiCTR2300068127Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Henagliflozin arm with Placebo arm (2 arms). Primary endpoints: DNA methylation clock and Telomere length. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2300068127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068127.